The APOE4 Gene and Dementia Risk: Should You Get Tested?

If there is one gene that neurologists and longevity researchers pay the most attention to, it is APOE4. This genetic variant, carried by roughly one in four people worldwide, is the single strongest genetic predictor of late-onset Alzheimer’s disease. Understanding what APOE4 is, whether you carry it, and what you can do about it has become one of the most important questions in preventive medicine.

What Is the APOE Gene?

APOE stands for apolipoprotein E — a protein involved in fat metabolism and, critically, in the transport and clearance of cholesterol and other lipids in the brain. The gene has three main variants (alleles): APOE2, APOE3, and APOE4. APOE3 is the most common, carried by approximately 78% of the population. APOE2 is relatively rare (around 8%) and is actually associated with a lower risk of Alzheimer’s. APOE4 is carried by approximately 25% of people and dramatically increases Alzheimer’s risk.

Because you inherit one copy from each parent, you can carry: no APOE4 alleles (most common), one copy (heterozygous, about 22% of people), or two copies (homozygous, about 2-3% of people). Each combination carries a different risk profile.

How Much Does APOE4 Increase Alzheimer’s Risk?

The numbers are significant:

• APOE3/3 (no APOE4): Baseline population risk (~10-12% lifetime risk after age 65)
• APOE3/4 (one copy): 2-3x increased risk compared to APOE3/3
• APOE4/4 (two copies): 8-12x increased risk; some studies report lifetime Alzheimer’s risk as high as 30-55% in APOE4 homozygotes

APOE4 also affects disease timing: carriers tend to develop Alzheimer’s 5-10 years earlier than non-carriers. In APOE4/4 homozygotes, the average age of onset is approximately 68 years — compared to 84 years in APOE3/3 individuals.

Why Does APOE4 Increase Alzheimer’s Risk?

APOE4 appears to impair the brain’s ability to clear amyloid beta — the protein that accumulates into plaques characteristic of Alzheimer’s disease. The APOE4 variant is less efficient at facilitating amyloid clearance than APOE3 or APOE2, leading to accelerated plaque accumulation over decades. APOE4 also impairs the function of the blood-brain barrier and mitochondria in neurons, and promotes a more pronounced inflammatory response in the brain.

Should You Get Tested for APOE4?

This is a complex decision with significant psychological implications. Arguments for testing:

• Knowing your status enables early, targeted preventive action during the most impactful window
• APOE4 status affects other health decisions — APOE4 carriers may have different responses to certain medications and should monitor cardiovascular health especially closely
• Commercial genetic tests (23andMe, Ancestry) include APOE4 results; direct-to-consumer availability has made this information widely accessible

Arguments against testing (or for careful preparation):

• A positive result causes significant anxiety in some people, potentially without immediate actionable consequences
• Genetic counselling is strongly recommended before and after testing to contextualise the result appropriately
• Current preventive options, while meaningful, cannot eliminate Alzheimer’s risk even for carriers

What APOE4 Carriers Should Do Differently

Critically, carrying APOE4 is not a fixed sentence. Lifestyle factors significantly modify the risk associated with the gene. Research on APOE4 carriers specifically shows:

• Exercise is exceptionally powerful: Regular aerobic exercise reduces brain amyloid accumulation and improves cognitive outcomes specifically in APOE4 carriers to a greater degree than non-carriers
• Sleep quality is critical: The brain’s glymphatic system — which clears amyloid during sleep — is the primary clearance mechanism impaired by APOE4. Prioritising 7-9 hours of quality sleep is among the most targeted interventions available
• Mediterranean diet: APOE4 carriers show stronger cognitive benefits from Mediterranean-style eating patterns than non-carriers in multiple studies
• Cardiovascular risk management: APOE4 carriers have elevated cardiovascular disease risk alongside Alzheimer’s risk; aggressive management of blood pressure, cholesterol, and blood sugar is essential
• Avoid head injuries: Traumatic brain injury interacts with APOE4 to dramatically accelerate Alzheimer’s pathology; avoiding contact sports or always wearing helmets is particularly important
• Limit alcohol: APOE4 carriers appear to be more susceptible to alcohol-related brain damage than non-carriers

Expert Perspective

“When a patient comes to me having tested APOE4 positive, the message I want to convey is clear: this is actionable information, not a verdict. The research is unambiguous that APOE4 carriers who exercise regularly, prioritise sleep, manage their cardiovascular risk factors, and eat well have dramatically better outcomes than carriers who do not. The gene loads the gun — but lifestyle determines whether it fires.”

Important Caveats

• APOE4 is a risk factor, not a diagnosis — many APOE4 carriers never develop Alzheimer’s disease
• Many people develop Alzheimer’s without carrying APOE4; the gene explains roughly 20-25% of genetic risk
• Genetic counselling is strongly recommended before taking any commercial genetic test that includes APOE status

Frequently Asked Questions

How common is the APOE4 gene?

Approximately 25% of people carry at least one copy of APOE4. Around 2-3% carry two copies (homozygous APOE4/4), which carries the highest risk.

Can you get tested for APOE4 in India?

Yes. APOE genotyping is available through specialist neurology clinics and some diagnostic labs in major cities. International services like 23andMe also report APOE4 status, though accessing raw data requires specific health upgrade subscriptions.

If I carry APOE4, will I definitely get Alzheimer’s?

No. Many APOE4 carriers never develop Alzheimer’s disease. The gene increases risk but does not determine outcome. Lifestyle factors significantly modify the risk associated with the gene.

Does knowing APOE4 status help with Alzheimer’s treatment?

Increasingly yes. Several new Alzheimer’s drugs (including lecanemab and donanemab) have different safety and efficacy profiles in APOE4 carriers — making genetic status a clinically relevant factor in treatment decisions. This is expected to become more important as the drug pipeline expands.

Related: The New Alzheimer’s Blood Test for India | Dementia Is Not Inevitable: What You Can Do | Brain Health and Alzheimer’s Prevention Guide